A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Human Genome Sciences Inc.

Criteria

Inclusion Criteria:

• Confirmed advanced solid malignancy

• Life expectancy of at least 3 months

• Age 18 years or older

• Acceptable liver function

• Acceptable renal function

• Acceptable hematologic status

Exclusion Criteria:

• Received investigational (not yet approved by a regulatory authority)agent within 4 weeks before enrollment.

• Received non-investigational agent within 3 weeks before enrollment.

• Progressive CNS involvement including the need of corticosteroids

• Pregnant or breast-feeding women

• Active, uncontrolled bacterial, viral, or fungal infections within 2 weeks of Cycle 1 Day 1

• Known HIV infection